Dr Adrián Povo Retana, CSIC, Spain
Dr. Adrián Povo Retana is a distinguished postdoctoral researcher at the Instituto de Investigaciones Biomédicas Alberto Sols 🏥🔬. With expertise in immunometabolism, biomedicine, and molecular biology, his research focuses on immune modulation in diseases like cancer and cardiovascular conditions 🧬💉. He earned his Ph.D. in Biociencias Moleculares from the Universidad Autónoma de Madrid 🎓 in 2022, after completing a Master’s in Biochemistry, Molecular Biology, and Biomedicine at Universidad Complutense de Madrid. His pioneering studies explore novel immunomodulatory therapies, and he actively supervises Ph.D. students 👨🏫📚. A key contributor to R&D projects, he investigates therapeutic applications of calcifediol in lymphoma and heart disease ❤️. As an author of high-impact publications and a collaborator on competitive research projects, his work advances cutting-edge biomedical treatments. His dedication to scientific excellence makes him a strong candidate for the Best Researcher Award 🏅🔍.
Publication Profile
Scopus
Education 🎓
- Doctorate in Biociencias Moleculares (Ph.D.) 🧬🔬
- Institution: Universidad Autónoma de Madrid
- Graduation Date: 18/11/2022
- Master’s in Biochemistry, Molecular Biology, and Biomedicine 🏥🧪
- Institution: Universidad Complutense de Madrid
- Graduation Date: 20/07/2017
- Graduado en Biotecnología (Bachelor’s in Biotechnology) 🧫🧑🔬
- Institution: Universidad Francisco de Vitoria
- Graduation Date: 01/10/2015
- Título Propio in Research Methodology in Biotechnology 📊🔍
- Institution: Universidad Francisco de Vitoria
- Graduation Date: 01/10/2015
Experience
- Postdoctoral Researcher 🏥🔍
- Institution: Instituto de Investigaciones Biomédicas Alberto Sols
- Duration: 18/11/2022 – Present
- Predoctoral Researcher 📖🧪
- Institution: Instituto de Investigaciones Biomédicas Alberto Sols
- Duration: 15/06/2017 – 17/11/2022 (5 years, 5 months)
🔹 Supervision of Ph.D. Theses 🎓📚
- “Immunomodulatory Effects of Ecteinascidins” – Universidad Autónoma de Madrid (2024)
- “Vitamin D and FICZ Role in Immune Regulation” – Universidad Autónoma de Madrid (2024)
- “Effect of 25-OH-D in Human Cell Cultures” – Universidad Complutense de Madrid (2023)
Awards & Honors
Recipient of the prestigious Chinese Government Scholarship, Dr. Adrián Povo Retana has established a remarkable academic and research career. Their dedication to innovation and scientific excellence earned them a nomination for the Best Young Researcher Award 🏅, highlighting their contributions to cutting-edge research. Securing multiple competitive research grants 💰, they have led impactful projects that drive advancements in their field. As a contributing author in high-impact journals 📄, their work has gained international recognition. Additionally, serving as a key investigator in major R&D projects 🔬, they play a crucial role in pioneering discoveries and technological advancements. Their commitment to academic excellence and research leadership continues to shape the future of science. 🌟
Research Focus
Dr. Adrián Povo Retana’s research revolves around immunometabolism, biomedicine, and immune system modulation 🏥🧬. His studies focus on the role of Vitamin D and nuclear receptors (VDR and AhR) in immune responses, particularly in cancer therapy and cardiovascular diseases ❤️💉. He investigates the immunomodulatory actions of compounds like trabectedin and lurbinectedin, contributing to novel therapeutic strategies against inflammation-related diseases. His work in macrophage and T-cell metabolism has led to new insights into anti-inflammatory treatments 🦠🔬. As a principal investigator in multiple state-funded R&D projects, he explores the therapeutic potential of calcifediol in lymphoma and myocardial infarction. His groundbreaking research continues to shape the future of immunotherapy and molecular medicine 🚀🩺.
Publication Top Notes
1️⃣ “Immunometabolic Effect of Nitric Oxide on Human Macrophages Challenged With the SARS-CoV2-Induced Cytokine Storm” – Advanced Healthcare Materials, 2024
2️⃣ “Immunometabolic Actions of Trabectedin and Lurbinectedin on Human Macrophages: Relevance for Their Anti-Tumor Activity” – Frontiers in Immunology, 2023